Syndax 1H FY26 net loss narrows to $49.4 million; 2Q FY26 revenue rises 92% to $72.8 million
SNDX•Half-year loss narrows and spending rises
- Net loss attributable to common stockholders narrowed to $49.4 million for the six months ended June 30, 2026, from $71.8 million a year earlier.
- R&D expense increased to $68 million from $62.2 million, due to higher spending on frontline revumenib trials in AML.
- Guidance was unchanged for 2026 operating expenses of about $400 million excluding $50 million of non-cash stock compensation.
- Phase 2 axatilimab data in IPF and frontline cGVHD are expected in 4Q26.
2Q revenue rises on Revuforj and Niktimvo
- Syndax posted 2Q26 revenue of $72.8 million, up 92% year over year, driven by Revuforj net revenue of $54.7 million, up 91%.
- Niktimvo net revenue rose 67% from a year earlier to $60.3 million, translating to $18.1 million of collaboration revenue for Syndax.
Related News
MEC Q2 net loss widens to $2.1 million; net sales rise 23.2% year over year to $163 million
MEC•
Kodak outlines growth principles, capital allocation framework in investor presentation
KODK•
